BioPharma Resources

Drug Trial Radar · NCT04646889

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

A Phase 1, Pharmacokinetic and Pharmacodynamic Study of AR882 in Adult Volunteers With Various Degrees of Renal Impairment

Last checked: Nov 19, 2026Latest source record: Aug 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Jan 14, 2021

Primary completion

Jun 27, 2022

Study completion Jun 27, 2022

Sponsor

Lead sponsor
Arthrosi TherapeuticsIndustry
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
Nov 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.

Conditions

  • Renal Impairment

Interventions

  • AR882 Single DoseDrug

    A single dose of AR882

  • AR882 Multiple DoseDrug

    AR882 taken once daily for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the curve (AUC) for plasma following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
  2. Time to maximum plasma concentration (Tmax) following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
  3. Maximum plasma concentration (Cmax) following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
  4. Terminal half-life (t 1/2) following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
  5. Amount excreted (Ae) into urine following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
  6. Renal clearance (CLr) following a single dose of AR882 in subjects with renal impairment and normal renal functionTime frame: 6 days
  7. AUC for plasma following multiple doses of AR882 in subjects with renal impairment and normal renal functionTime frame: 15 days
  8. Tmax following multiple doses of AR882 in subjects with renal impairment and normal renal functionTime frame: 15 days
  9. Cmax following multiple doses of AR882 in subjects with renal impairment and normal renal functionTime frame: 15 days
  10. t 1/2 following multiple doses of AR882 in subjects with renal impairment and normal renal functionTime frame: 15 days

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Arthrosi Investigative Site

    Orlando, Florida

  • Arthrosi Investigative Site

    Dallas, Texas

  • Arthrosi Investigative Site

    Auckland, New Zealand

  • Arthrosi Investigative Site

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.